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Introduction: Alternative splicing distinguishes normal and pathologic cells. High levels of oncoprotein survivin
recognise patients with severe rheumatoid arthritis (RA). Here, we assess clinical relevance of alternative splicing
of survivin in leukocytes of peripheral blood (PBMC) and bone marrow (BM) in RA patients.
Method: Transcription of survivin wild-type (survivin-WT), survivin-2B and survivin-ΔEx3 was measured in 67
randomly selected RA patients and in 23 patients before and after B cell depletion with rituximab. Analysis was done in
relation to disease activity, anti-rheumatic treatment and serum levels of rheumatoid factor (RF) and survivin.
Results: Survivin-WT was the dominant splice variant equally expressed in T and B cells, while survivin-2B and
survivin-ΔEx3 were higher in B cells. High disease activity (DAS28>5.1) was associated with an excess of survivin-WT
and low ratios between survivin-2B/WT (p=0.035) and survivin-ΔEx3/WT in PBMC. Depletion of B cells by rituximab
caused a decrease in survivin-WT (p=0.005) in PBMC, increasing the ratio between survivin-2B/WT (p=0.009) and
survivin-ΔEx3/WT (p=0.001) in BM. This increase in survivin-2B/WT was associated with reduction in CD19+ BM cells
(r=0.929, p=0.007), RF (IgM, r=0.857, p=0.024; IgA, r=0.739, p=0.021), and DAS28 (0.636, p=0.054). The increase in
survivin-ΔEx3 in BM was associated with a reduction of CD19+ BM cells (r=0.714, p=0.058) and DAS28 (r=0.648,
p=0.049), while survivin-ΔEx3/WT was associated with RF (IgG, r=0.882, p=0.016).
Conclusion: This study demonstrates that the suppressed diversity of survivin splicing in leukocytes may attribute to
adverse self-recognition in RA. Depletion of autoantibody producing B cells improves the balance of survivin splicing.Introduction
Survivin is a multifunctional protein that belongs to the
inhibitor of apoptosis (IAP) family and is encoded by the
BIRC5 gene, which is found at chromosome 17q25 in
humans [1]. Survivin is a marker of malignant cell
growth expressed in a vast range of cancers (reviewed
by [2]). In normal tissues, survivin is essential for fetal
development and for regeneration and repair of
damaged tissues [3].
Survivin has been identified in cytoplasm, nucleus and
mitochondria and has different functions within these
cellular localisations [4]. Nuclear survivin plays a part in
regulation of cell division, whereas mitochondrial and
cytoplasmic survivin inhibits apoptosis and promotes* Correspondence: maria.bokarewa@rheuma.gu.se
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creativecommons.org/publicdomain/zero/1.0/cell proliferation [5, 6]. Survivin is upregulated during
the G2/M phase in mitosis and forms a chromosomal
passenger complex together with inner centromere pro-
tein, Aurora B and borealin, aiding formation of micro-
tubules and their attachment of kinetochores during
cytokinesis [7]. When released from the nucleus, survi-
vin displays anti-apoptotic functions. Cytoplasmatic sur-
vivin forms a complex with the X-linked IAPs (XIAP),
which enhances its stability against ubiquitin-dependent
degradation [8]. The XIAP–survivin complex binds
caspase-3, preventing its pro-apoptotic functions. In the
mitochondrial compartment, survivin binds pro-apoptotic
protein Smac/Diablo that inhibits its release and activation
of caspase-9 [9].
The mRNA of human survivin has six different splice
variants of which wild-type survivin (survivin-WT, 142
amino acids), survivin with an insert of additional exon
2 (survivin-2B, 165 amino acids) and survivin with de-
pletion of exon 3 (survivin-ΔEx3, 137 amino acids)rticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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Age (years) 56.6 (24–79) 59.4 (29–79)
Female/male 65/2 21/2
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of mRNA expression from the BIRC5 gene. All splice vari-
ants are identical in the N-terminus containing the BIR
domain and differ in the carboxyl region. Survivin-WT
and survivin-2B are actively moved out from the nucleus
binding the carboxyl region to an exportin-1 [12, 13].
Survivin-ΔEx3 lacks the export signal, which is thought to
keep it in the nucleus and in the mitochondria [5, 14].
Survivin-WT can form homodimers in solution and the
balance between the dimer and monomer forms of survi-
vin seems to regulate its ability to translocate and function
in cellular compartments [15]. Additionally, survivin-WT
may form heterodimers with survivin-2B and survivin-
ΔEx3, which disrupts their normal function in cell death
regulation and cell proliferation control [10, 14, 16].
Survivin-2B has a pro-apoptotic function [12, 17, 18]
interfering with and blocking tubulin polymerisation and
inducing mitochondria-dependent apoptosis [12, 17].
Survivin-ΔEx3 has dual functions. Similar to survivin-WT,
it may inhibit apoptosis by preventing a XIAP-dependent
activation of caspases in the cytoplasm and a release of
Smac/Diablo from mitochondria [16, 19, 20]. In non-
cancer cells, survivin-ΔEx3 mediates cell spreading, migra-
tion and stability [21]. If overexpressed, survivin-ΔEx3 also
has a pro-apoptotic function and inhibits cell growth and
proliferation in cell cultures [2, 22–24].
Overexpression of survivin in non-cancerous processes
has been linked to inflammation, presumably contributing
to the decreased apoptosis in the T cells of cerebrospinal
fluid in multiple sclerosis [25], in skin lesions of patients
with psoriasis [26] and in synovial tissue [27, 28] of
patients with rheumatoid arthritis (RA). Reports on the
role of survivin in the function of pluripotent stem cells
[29, 30] and in the development of mature T cells [31] re-
serve a place for survivin-dependent mechanisms in im-
mune responses. Our recent studies have shown an
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Fig. 1 Survivin splice variants. Exon organisation in mRNA of human
most frequent survivin splice variants, which comprise 98 % of
mRNA expression from the BIRC5 gene. Splice variants were
measured using the same forward primer located in the N-terminus.
The reverse primers were located within exon 3 (for survivin-WT),
within the inserted sequence derived from intron 2 (for survivin-2B)
and within the unique sequence of exon 4 (for survivin-ΔEx3).
Arrows indicate positions of PCR primers. Sequences for each primer
can be found in Methods. UTR untranslated region, WT wild typepathogenesis of RA: smoking [32], carriage of HLA-DRB1
antigen [33] and production of the RA-specific autoanti-
bodies, rheumatoid factor (RF) and antibodies to citrulli-
nated peptides (ACPA) [33–35]. High levels of survivin
are associated with poor prognosis in RA predicting pro-
gressive joint damage and low responsiveness to anti-
rheumatic treatment [35, 36].
In the present study we ask whether differential spli-
cing of the survivin gene is of clinical relevance in RA.
The measurement of three major splice variants of survi-
vin showed that the proportional composition between
survivin-WT and survivin-2B or survivin-ΔEx3 rather
than the quantity of individual variants in leukocytes of
peripheral blood (peripheral blood mononuclear cells
(PBMCs)) and bone marrow (BM) is clinically important.
An excess of survivin-WT and low survivin-2B/WT and
survivin-ΔEx3/WT ratios in PBMCs distinguished pa-
tients with high disease activity, while anti-rheumatic
treatment led to a gradual increase of the survivin-2B/
WT ratio. Therapeutic B-cell depletion changed the pro-
file of survivin splice variants in leukocytes of RA pa-
tients by reducing survivin-WT and favouring splicing of
pro-apoptotic survivin-2B and survivin-ΔEx3. This
change in survivin composition correlated to the reduc-
tion of B cells in BM, reduction in serum levels of RF
and reduction in the disease activity. The association be-
tween survivin splicing and the autoreactive nature of B
cells revealed a connection of survivin with the func-
tional immune processes in RA.Disease duration (years) 10.2 (1–40) 13.1 (2–33)
RF positive (%) 83.6 96.0
ACPA positive (%) 71.7 83.0
DAS28 3.86 (1.38–6.77) 5.89 (4.6–6.8)
Methotrexate (n) 55 (82.1 %) 18 (78.3 %)
Dose (mg/week) 18.2 (7.5–25) 18.0 (10–25)
Anti-TNFα 10 (14.9 %) 0
Rituximab 13 (19.4 %) 9 (39.1 %)
Anti-IL-6R 2 (3.0 %) 0
CTLA4 1 (1.5 %) 0
Serum survivin (ng/ml) 18.5 (0.02–306.21) 2.07(0.10–14.9)
Values are mean and minimum and maximum are shown
ACPA antibodies against cyclic citrullinated peptides, CTLA4 cytotoxic T
lymphocyte associated protein, DAS28 Disease Activity Score based on the
evaluation of 28 joints, IL-6R interleukin 6 receptor, RF rheumatoid factor,
TNFα tumour necrosis factor alpha
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Patients
A total of 67 randomly selected patients with established
RA who attended the Rheumatology Clinic at Sahlgrenska
University Hospital, Gothenburg, were included in the
study. All patients fulfilled the 1987 Rheumatoid Arthritis
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Fig. 2 Levels of survivin splice variants in peripheral blood mononuclear ce
arthritis. a mRNA levels of survivin-WT, survivin-2B and survivin-ΔEx3 were
the relative quantity (RQ) of the reference group PBMC within each splice v
c Total mRNA level of survivin splice variants in PBMC samples, expressed a
d Serum levels of survivin within the allocated groups. Boxes represent the
values and error bars show the range. e Disease Activity Score (DAS28) with
the group; horizontal lines indicate median values and error bars show the
for patients in remission (DAS <3.2), in active RA (DAS28 3.2–5.1) and in hig
group. h Survivin-2B/WT ratio in PBMCs of patients with different treatmen
DMARD disease-modifying anti-rheumatic drug, MTX methotrexate, +anti-TN
combination of MTX and rituximab, RA rheumatoid arthritis, WT wild typecharacteristics of the patients are presented in Table 1.
At the time of blood sampling, 55 patients (82 %) were
treated with methotrexate (MTX), and 23 of 55 patients
combined MTX with biologics (tumour necrosis factor-
alpha (TNFα) inhibitors, 10 patients; rituximab (RTX), 13
patients). One patient was treated with abatacept as mono-
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lls (PBMCs) and bone marrow (BM) of patients with rheumatoid
measured in 67 PBMC samples and 23 BM samples and expressed as
ariant. b Combination of the splice variants in 67 PBMC samples.
s the RQ of survivin-WT in the group containing all splice variants.
25th–75th percentile of the group; horizontal lines indicate median
in the allocated groups. Boxes represent the 25th–75th percentile of
range. f Survivin-2B/WT ratio and g survivin-ΔEx3/WT ratio in PBMCs
h active RA (DAS28 >5.1). Lines indicate mean values within each
t modalities. Horizontal lines indicate median value for the group.
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Fig. 3 Survivin splice variants in CD19+ and CD4+ cells. a mRNA levels of survivin-WT, b survivin-2B and c survivin-ΔEx3 were measured in CD19+
and CD4+ cells isolated from the peripheral blood of RA patients (n = 4) and healthy controls (n = 3). Cells were activated for 72 hours to permit
survivin production. Error bars show the range and horizontal lines indicate median values. Comparison between the groups was by Mann–Whit-
ney statistics. dCT difference in cycle threshold, RA rheumatoid arthritis, WT wild type
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rheumatic drugs (DMARDs) at the time of the study.
Another 23 RA patients were treated with 1000 mg B
cell depleting monoclonal anti-CD20 antibodies (RTX;
Hoffman-La Roche Ltd, Basel, Switzerland) provided
intravenously on days 1 and 15 as described elsehere [38].
Disease activity was assessed at the day of blood samplingTable 2 Effect of rituximab treatment in patients with rheumatoid
arthritis
Before RTX After RTXa
DAS28 score 5.89 ± 0.6 4.34 ± 0.7
Rheumatoid factor (IU/ml)
IgG 41.5 ± 29.3 22.7 ± 19.5*
IgM 67.2 ± 31.1 50.2 ± 38.3
IgA 41.0 ± 38.3 25.0 ± 19.5
WBC count (×109/l)
PBMCs 6.5 ± 3.1 7.8 ± 3.2
BM 2.1 ± 1.4 2.6 ± 1.6
CD19+ (%)b
PBMCs 7.7 ± 3.8 0
BM 9.4 ± 4.3 1.3 ± 1.2†
CD3+ (%)b
PBMCs 45.9 ± 15.8 42.5 ± 12.9
BM 28.0 ± 9.8 29.4 ± 16.5
Values presented as mean ± standard deviation, n = 23
a Samples 1–3 months after RTX treatment
b From the lymphocyte population
* p = 0.008
† p <0.0001
BM bone marrow, DAS28 Disease Activity Score based on evaluation of 28 joints,
PBMC peripheral blood mononuclear cells, RTX rituximab, WBC white blood cellby evaluation of 28 joints for swelling and tenderness, and
the Disease Activity Score (DAS28) was calculated.
Ethical approval
The study was approved by the Ethical Committee of
the Sahlgrenska University Hospital. All patients gave
written informed consent before giving blood and bone
marrow samples.
Blood and bone marrow sampling
Serum was prepared by centrifugation for 15 minutes at
800 × g, aliquoted and stored at −20 °C until analysed.
PAXgene Blood RNA tubes (PreAnalytix, Hombrechtikon,
Switzerland) were used for mRNA preparation according
to the manufacturer’s recommendations. BM samples were
obtained from 23 patients before RTX treatment by as-
piration from the crista iliaca as described previously
[38]. Blood and BM sampling was repeated 1 month or
3 months after the RTX treatment.
Cell isolation and stimulation
Mononuclear cells from the peripheral blood (PBMCs)
and BM were isolated by density gradient separation on
Lymphoprep™ (Axis-Shield PoC As, Oslo, Norway). For
in-vitro experiments, CD19+ B cells and CD4+ T cells were
separated from the isolated PBMCs using Dynabeads®
(Invitrogen, Carlsbad, CA, USA). The separated cell popu-
lations were resuspended in Dynal buffer (2 % bovine
serum albumin (BSA) and 1 mM ethylenediamine tetraa-
cetic acid (EDTA) in phosphate-buffered saline (PBS)) at a
concentration of 2 × 106 cells/ml. CD19+ cultures were
stimulated with Pam3Cys (10 μg/ml; EMC Microcollec-
tions, Tubingen, Germany) and CD4+ cultures were stim-
ulated with Concanavalin A (5 μg/ml; Sigma, St. Louis,
Turkkila et al. Arthritis Research & Therapy  (2015) 17:175 Page 5 of 10MO, USA). Cells were collected after 72 hours, washed
and lysed in RLT lysis buffer for RNA analysis.
Serological measurements
Serum levels of survivin were measured using a
matched antibody pair by a sandwich enzyme-linked
immunosorbent assay (ELISA) (DYC647; R&D Systems,
Minneapolis, MN, USA) as described previously [39].
Samples were diluted 1:10 and the detection limit was
0.1 ng/ml. Values above 0.45 ng/ml were defined as
positive. Total levels of RF and ACPA antibodies were
measured at the Laboratory of Clinical Immunology at
Sahlgrenska University Hospital. RF of IgG, IgM and IgA
subclasses were analysed from serum, diluted 1/1000, using
an ELISA assay [38].
RNA isolation and SYBR Green-based real-time PCR
Total RNA was extracted using the RNeasy Mini Kit
(Qiagen, Valencia, CA, USA) and Paxgene Blood miRNA
kit (Qiagen) according to the manufacturer’s recom-
mendations. The RNA concentration and quality were
measured using a Nanodrop spectrophotometer (ND1000
Spectrophotometer) and Experion™ RNA StdSens Analysis
chip (Bio-Rad Laboratories, Hercules, CA, USA). cDNA
was synthesised using the Applied Biosystems (Foster
City, CA, USA) High-Capacity cDNA Reverse Tran-
scription Kit according to the manufacturer’s recom-
mendations. Transcription of survivin was assessed
using SYBR Green qPCR Mastermix (SABiosciences,
Qiagen) and ViiA™ 7 Real-Time PCR (Applied Biosys-
tems). All samples used the identical forward primer
GACCACCGCATCTCTACATTC and splice variant spe-
cific reverse primers (Fig. 1): survivin-WT, TGCTTTT
TATGTTCCTCTATGGG; survivin-2B, AAGTGCTGGT
ATTACAGGCGT; and survivin-ΔEx3, ATTGTTGGTT
TCCTTTGCATG [40] (Sigma). Melting curves for each
PCR were performed between 60 and 95 °C to ensure spe-
cificity of the amplified product. All samples were run in
duplicate with glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) as a reference gene and with a negative control.
Expression levels of target genes were normalised to
GAPDH to obtain the difference in cycle threshold (dCt).
Six samples from healthy subjects were used as the refer-
ence group. The relative quantity (RQ) was calculated using
the ddCt method.
Statistical evaluation
Correlation between variables was analysed by Spearman
test. Differences between two groups were tested by
Mann–Whitney test and chi-square analysis. All tests were
two-tailed and conducted with a 95 % confidence interval
(CI) and p <0.05 was considered significant. Statistical
analyses were performed using the Prism programme
(v.6.x; GraphPad software, San Diego, CA, USA).Results
Diversity of survivin splicing in leukocytes of the
peripheral blood and BM
Transcription of survivin-WT, survivin-2B and survivin-
ΔEx3 was analysed in 67 PBMC samples and in 23 BM
samples of randomly selected RA patients. Clinical char-
acteristics of the patients are presented in Table 1. The
RQ of each survivin splice variant was much higher in
the BM compared with PBMCs and showed approxi-
mately 20 times excess for survivin-WT, 15 times for
survivin-2B, and seven times for survivin-ΔEx3 (Fig. 2a).
Survivin-WT was the predominant splice variant present
in all PBMC and BM samples. Survivin-2B and survivin-
ΔEx3 were undetectable in 19–43 % of PBMC samples
and 4–9 % of BM samples, which resulted in a diversity
of survivin splicing in RA leukocytes (Fig. 2b). The level
of survivin-WT was significantly higher (p = 0.04) in
the samples combining expression of all three splice
variants (Fig. 2c). The univariate analysis revealed no
significant association between the levels of individual
survivin splice variants and clinical parameters of RA
(all r <0.3; data not shown). Serum levels of survivin
(Fig. 2d), DAS28 (Fig. 2e) and disease duration (data
not shown) were similar in the groups with different
combinations of survivin splicing.
Composition of survivin splicing and clinical signs of RA
Since survivin-WT may form dimers with survivin-2B
and survivin-ΔEx3 opposing its functions, we studied
the survivin-2B/WT (n = 54) and survivin-ΔEx3/WT
(n = 38) ratios in PBMCs where both splice variants
were present. We found that survivin-2B/WT was low
and reflected a significant excess of survivin-WT in the
patients with high disease activity (DAS28 >5.1)
(Fig. 2f ). Similarly, low survivin-ΔEx3/WT ratio with a
relative excess of survivin-WT was found in PBMC
samples irrespectively of DAS28 (Fig. 2g).
To study whether anti-rheumatic treatment affects
the survivin-2B/WT ratio, we compared survivin spli-
cing in patients with different treatment modalities.
The survivin-2B/WT ratio increased gradually with the
intensification of immunosuppression. This ratio was
lowest in the patients having no DMARD treatment,
and tended to increase in the patients treated with a
combination of methotrexate with TNF inhibitors
(Fig. 2h). The patients treated with a combination of
MTX and RTX had further increase of the survivin-2B/
WT ratio.
Difference of survivin splicing in T and B lymphocytes
To study composition of survivin splice variants pro-
duced by T and B lymphocytes, we separated CD4+ T
cells and CD19+ B cells from PBMCs of four randomly
selected RA patients (two women, two men) and of
Turkkila et al. Arthritis Research & Therapy  (2015) 17:175 Page 6 of 10three healthy women. The separated cells were acti-
vated in vitro to permit survivin production, and
mRNA levels of survivin-WT, survivin-2B and
survivin-ΔEx3 were measured. The levels of survivin-
WT were similar in CD4+ and CD19+ cells (Fig. 3a),
while survivin-2B and survivin-ΔEx3 were significantly
higher in CD19+ B cells (Fig. 3b and c, respectively).
No significant difference in survivin-2B/WT and
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Fig. 4 Survivin splicing in blood and bone marrow leukocytes of RA patien
and after RTX treatment. mRNA level of b survivin-WT and c survivin-2B in
leukocytes of 23 patients before and 1–3 months after RTX treatment. d Su
e Survivin-ΔEx3 in PBMCs and BM before and 1–3 months after RTX treatm
Boxes represent the 25th–75th percentile of each group, horizontal lines ind
between groups performed with Mann–Whitney statistics. dCT difference in
dehydrogenase, RQ relative quantityB-cell depletion modifies survivin splicing in BM
and PBMCs
To assess whether B-cell depletion changed the spli-
cing of the survivin gene we analysed the paired PBMC
and BM samples of 23 RA patients before and after
RTX treatment (Table 2). The RTX treatment resulted
in the complete depletion of B cells from the PBMCs
and a significant reduction of the B-cell population in
the BM [40]. Consequently, a decrease of RF and of the
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peripheral blood mononuclear cell (PBMC) and bone marrow (BM)
rvivin-2B/WT ratio in BM before and 1–3 months after treatment.
ent. f Survivin-ΔEx3/WT ratio in BM before and after RTX treatment.
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Fig. 5 Correlations between clinical parameters of RA and survivin
splice variants in BM after rituximab (RTX) treatment. Correlations
between survivin splice variants and a change of CD19+ B cells,
b levels of rheumatoid factor (RF) and c Disease Activity Score
(DAS28) in 23 patients after RTX treatment. 1Correlation to survivin
splice variants before RTX treatment. 2Correlation to survivin splice
variants after RTX treatment. Correlations were calculated with
Spearman’s analysis. dCT values were used for the individual splice
variants, and RQ values were used for the survivin-2B/WT and
survivin-ΔEx3/WT ratios. WT wild type
Turkkila et al. Arthritis Research & Therapy  (2015) 17:175 Page 7 of 10in the BM before RTX treatment was associated with
higher numbers of BM CD19+ B cells (r = 0.857, p =
0.024).
The B cell depletion in PBMCs was followed by a de-
crease of survivin-WT (Fig. 4b). The individual expres-
sion of survivin-2B in PBMCs and BM showed no
statistical change (Fig. 4c). The change was, however,
sufficient to attain a significant increase of the
survivin-2B/WT ratio in BM (Fig. 4d). The reduction
in survivin-WT and the change of the survivin-2B/WT
ratio correlated to the reduction of the BM CD19+ B
cells (Fig. 5a) and of RF levels (Fig. 5b). Remarkably,
the association was strong for low-affinity RF-IgM
antibodies and for the high-affinity RF-IgA. The reduc-
tion in survivin-WT and the increase of the survivin-
2B/WT ratio was in direct proportion to the decrease
of clinical activity of arthritis (Fig. 5c).
Following RTX treatment, survivin-ΔEx3 was increased
in BM (Fig. 4e), which caused a significant increase of the
survivin-ΔEx3/WT ratio (Fig. 4f). Analogously with
survivin-2B, the change in survivin-ΔEx3 after RTX treat-
ment correlated to a decrease in the BM CD19+ B cells
(Fig. 5a) and in the serum survivin levels (r = 0.928, p =
0.008). The survivin-ΔEx3/WT ratio showed a correlation
to the reduction of the high affinity RF-IgG antibodies
(Fig. 5b).
Discussion
This study shows that transcription of survivin in the
leukocytes of PBMCs and BM has a tight connection to
the pathogenesis of RA and to the functional auto-
immune processes in these compartments. We present
evidence that changes in the pattern of survivin splicing
may belong to the clinically important events in RA.
Survivin-WT is the dominant survivin splice variant in
PBMCs and BM of RA patients, followed by survivin-2B
and survivin-ΔEx3, which confirms the observations in
malignant cells and in pluripotent stem cells [29, 30,
41–43]. In the observational and in the B cell depletion
parts of this study, the excess of survivin-WT is con-
nected to high clinical activity of RA, suggesting that
survivin-WT favours inflammatory and aggressive profile
of leukocytes. Previous studies reported high expression
of survivin in lymphocytes infiltrating tissue lesions in
several non-cancer pathologies [25–28, 44]. However,
splicing composition of this expression was not assessed.
This study showed that B cells from peripheral blood of
RA patients and from healthy controls were recognised by
high production of survivin-2B and survivin-ΔEx3. The
low survivin-2B before RTX treatment and the increased
production of survivin-2B and survivin-ΔEx3 thereafter
was in direct relation to B cell numbers in the BM, and oc-
curred in parallel with a decrease in survivin-WT. This
observation leads us to suggest that IgD+ B cells depleted
Turkkila et al. Arthritis Research & Therapy  (2015) 17:175 Page 8 of 10by RTX [38] are either the major source of survivin-WT
or the suppressors of differential survivin splicing in other
cells giving priority to survivin-WT. The elimination of
IgD+ cells in BM of RA patients restrains the mechanisms
of survivin splicing control.
The formation of autoreactive B cells measured by the
levels of autoantibodies, RF and ACPA is a key to the aber-
rant immune responses in RA [45]. Depletion of B cells by
RTX decreases serum levels of RF and ACPA [46–48], and
leads to pronounced clinical improvement in RA patients
[49]. Additionally, the presence of autoantibody-producing
B cells has been indicated essential for the efficacy of
RTX treatment [50, 51]. Here, we demonstrate that the
reduction of serum RF-IgM had close association with a
decrease of survivin-WT and with the changes in
survivin-2B/WT ratio in the BM, suggesting that
survivin-WT belongs to the autoreactive nature of B
cells. RTX treatment affects homeostasis of B cells by
elimination of the naïve and short-lived memory B cell
from the peripheral blood and in the BM [38, 52, 53].
We also found that the proportional composition be-
tween the anti-apoptotic survivin-WT and pro-apoptotic
survivin-2B and survivin-ΔEx3 rather than the quantity
of the individual splice variants was of clinical relevance
in RA. Immunosuppressive treatment was associated
with gradual increase of the survivin-2B/WT ratio
(Fig. 6). Since both survivin-2B and survivin-ΔEx3 have
been shown to oppose survivin-WT [54], a restriction of
the anti-apoptotic function of survivin-WT in the cyto-
plasm and the mitosis-supporting function in theFig. 6 Graphic summary. Survivin-WT is by far the most prevalent variant o
marrow. Survivin-WT is known to be an efficient IAP, forming complexes w
X-linked inhibitor of apoptosis (XIAP) to inactivate caspase-3 (Casp3) and ca
in the formation of chromosomal passenger complex supporting mitosis. A
gested to form heterodimers with survivin-WT preventing its anti-apoptotic
characterised by low survivin-2B/WT and survivin-ΔEx3/WT ratio indicating
and particularly B-cell depletion with rituximab (RTX), increased the levels o
heterodimers with survivin-WT. The present study showed that this change
the number of CD19+ B cells, serum levels of autoantibodies (AB) and of thnucleus is expected. In the BM, this change in survivin
composition of B cells could affect the formation and
life-length of the antigen-experienced B cells, where the
immature subsets of B cells may utilise the higher pro-
duction of survivin-2B and survivin-ΔEx3 variants for
their maturation limiting RF production. In the setting
of RA, the excess of survivin-WT may be viewed as a
mechanism to control repopulation and survival of
autoantibody-producing B cells [38, 52]. Whether a reduc-
tion of survivin-WT or the changed balance in the com-
position of survivin splicing is responsible for the decrease
in RA activity, however, is yet to be determined.
The mechanisms controlling survivin splicing in healthy
cells and in pathology are poorly understood [24]. Aber-
rant regulation of survivin-2B and survivin-ΔEx3 has been
recognised as a negative prognostic factor during breast,
colorectal, renal and gastric carcinomas [2, 55]. The im-
portance of differential tissue expression of survivin splice
variants has been proposed, where diminished survivin-
2B is associated with poor proliferation control and pro-
gressing tissue expansion. This is concordant with the
results obtained in experimental arthritis demonstrating
that inhibition of survivin translation by small hairpin
RNA-expressing constructs results in the alleviation of
joint inflammation and bone destruction [56]. Survivin
inhibition achieved by these constructs was not splice
variant specific [39], but reduction in the predominant
splice variant, survivin-WT, could potentially have re-
stored a balance between the pro-apoptotic and anti-
apoptotic splice variants of survivin.f survivin in human leukocytes of the peripheral blood and of the bone
ith Smac/Diablo to prevent its release from mitochondria, and with
spase-9 (Casp9). Homodimers of survivin-WT in the nucleus participate
lternative splice variants survivin-2B and survivin-ΔEx3 have been sug-
and pro-mitotic functions. Active rheumatoid arthritis (RA) is
suppressed diversity of survivin splicing. The anti-rheumatic treatment,
f survivin-2B and survivin-ΔEx3, potentially supporting formation of
d composition of survivin splice variants associates with a decrease in
e disease activity in patients with rheumatoid arthritis. WT wild type
Turkkila et al. Arthritis Research & Therapy  (2015) 17:175 Page 9 of 10Conclusions
Alternative splicing is generally viewed as a mechanism
distinguishing healthy and pathologic cells. This study
extends this perspective and demonstrates that sup-
pressed diversity of survivin splicing occurred in active
RA as a part of autoimmune inflammation. Depletion of
autoreactive B cells contributes to changes of the survi-
vin splicing profile and decrease of autoantibody produc-
tion (Fig. 6).
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